Orphazyme A/S (ORPH)

$0.87

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol ORPH
Price $0.87
Beta 0.802
Volume Avg. 1.38M
Market Cap 37.272M
Shares () -
52 Week Range 0.5101-77.77
1y Target Est -
DCF Unlevered ORPH DCF ->
DCF Levered ORPH LDCF ->
ROE -144.20% Strong Sell
ROA -113.40% Strong Sell
Operating Margin -
Debt / Equity 156.67% Buy
P/E -
P/B 0.66 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ORPH news


Ms. Kim Stratton
Healthcare
Biotechnology
NASDAQ Global Select

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.